Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.
Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.
复制标题
DOI：
10.18632/oncotarget.6612
复制
发表时间：
2016-01-26
期刊：
影响因子：
--
通讯作者：
Zhou C
中科院分区：
文献类型：
--
作者：
Jiang T;Wang Y;Zhou F;Gao G;Ren S;Zhou C
Zeste同源物增强子2（EZH 2）是肿瘤抑制基因表观遗传沉默的潜在独立机制。我们对PubMed、EMBASE、Web of Science和科克伦图书馆进行了电子检索，以进行最新的荟萃分析。纳入了51项研究，共9444例患者。EZH 2高表达的患病率为0.54（95%CI：0.47-0.61）。EZH 2高表达与预后不良显著相关[总生存期：HR 1.54（95%CI：1.30-1.78），P < 0.000;无病生存期：HR 1.35（95%CI：1.00-1.71），P < 0.000]。在乳腺癌中，EZH 2高表达与组织学类型相关[OR：1.53（95 CI：1.13-2.06）; P < 0.006]，组织学分级[OR：1.62（95 CI：1.35-1.95）; P < 0.000]，雌激素受体（ER）阴性[OR：2.05孕酮受体（PgR）阴性[OR：1.42（95 CI：1.03-1.96）; P = 0.034]、HER-2阳性[OR：1.35（95 CI：1.08-1.69）; P = 0.009]和p53高表达[OR：1.66（95 CI：1.07-2.59）; P = 0.024]。这些结果表明EZH 2高表达可能是不同癌症的一个有希望的预后因子。EZH 2高表达与乳腺癌的病理类型、组织学分级、ER阴性、PgR阴性、HER-2阳性及p53高表达有关。
Enhancer of zeste homologue 2 (EZH2) is a potential independent mechanism for epigenetic silencing of tumor suppressor genes in cancer. We conducted an electronic search on PubMed, EMBASE, Web of Science, and Cochrane library to perform this up-to-date meta-analysis. Fifty-one studies with a total of 9444 patients were included. The prevalence of high EZH2 expression was 0.54 (95% CI: 0.47-0.61). High EZH2 expression was significantly associated with poorer prognosis [overall survival: HR 1.54 (95% CI: 1.30-1.78), P < 0.000; disease free survival: HR 1.35 (95% CI: 1.00-1.71), P < 0.000]. In breast cancer, high EZH2 expression correlated with histological types [OR: 1.53 (95CI: 1.13-2.06); P < 0.006], histological grade [OR: 1.62 (95CI: 1.35-1.95); P < 0.000], estrogen receptor (ER) negativity [OR: 2.05 (95CI: 1.67-2.52); P < 0.000], progesterone receptor (PgR) negativity [OR: 1.42 (95CI: 1.03-1.96); P = 0.034], HER-2 positivity [OR: 1.35 (95CI: 1.08-1.69); P = 0.009], and high p53 expression [OR: 1.66 (95CI: 1.07-2.59); P = 0.024]. These results suggest that high EZH2 expression may be a promising prognostic factor to different cancers. High EZH2 expression tends to correlate with pathological types, histological grade, ER negativity, PgR negativity, HER-2 positivity and p53 high expression in breast cancer.